A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, andAnti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected SolidTumors
Enrolling By Invitation
18 years - 99 years
All
Phase
N/A
124 participants needed
1 Location
Brief description of study
To evaluate an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors. A personalized vaccine, consisting of between 4 to 20 synthetic long peptides, will be generated for each patient and shall be administered as an adjuvanted vaccine, with the adjuvant Hiltonol.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Melanoma (cutaneous)NSCLCSCCHN (oral,oropharyngeal,hypopharyngeal,or laryngeal)Urothelial carcinoma (bladder,ureter,urethra,or renal pelvis)Renal cell carcinoma with a clear cell component
-
Age: 18 years - 99 years
-
Gender: All
Male or Female, Age 18 or older confirmed diagnosis of 1 of the following tumor types: a. Melanoma (cutaneous). b. NSCLC. c. SCCHN (oral, oropharyngeal, hypopharyngeal, or laryngeal). d. Urothelial carcinoma of the bladder, ureter, urethra, or renal pelvis that has predominantly transitional cell/urothelial features on histologic testing. e. Renal cell carcinoma with a clear cell component
Updated on
04 Aug 2024.
Study ID: 831324
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
